Financial Performance - The company's revenue for the year ended December 31, 2025, was HKD 51,305,000, representing a 25.9% increase from HKD 40,684,000 in 2024[3] - The operating loss for the year was HKD 40,476,000, compared to a loss of HKD 31,195,000 in the previous year, indicating a deterioration in operational performance[3] - The net loss attributable to the owners of the company was HKD 43,532,000, up from HKD 21,120,000 in 2024, reflecting a significant increase in losses[4] - The segment loss before tax for 2025 was HKD 45,378,000, compared to a loss of HKD 37,075,000 in 2024, indicating a deterioration in performance[30] - The group recorded a net loss of approximately HKD 45,378,000 for the year ending December 31, 2025, with net current liabilities and net liabilities amounting to approximately HKD 66,681,000 and HKD 102,901,000 respectively[13] - The group reported a total comprehensive loss of approximately HKD 49,001,000, an increase of about 30.3% from the previous fiscal year's loss of approximately HKD 37,596,000[76] Assets and Liabilities - The total assets of the company increased to HKD 80,443,000 in 2025 from HKD 75,054,000 in 2024, showing a growth of 7.9%[5] - The company's current liabilities rose to HKD 86,649,000 in 2025, compared to HKD 73,272,000 in 2024, indicating an 18.4% increase in financial obligations[5] - The total liabilities rose to HKD 183,344,000 in 2025, compared to HKD 180,404,000 in 2024, reflecting a slight increase in financial obligations[30] - The total equity increased to HKD 20,000,000 in 2025 following the issuance of an additional 1,220,000,000 shares[49] Cash Flow and Liquidity - The company’s cash and cash equivalents decreased to HKD 2,443,000 in 2025 from HKD 13,857,000 in 2024, reflecting a decline in liquidity[5] - The group plans to implement strict cost control measures to improve operating cash flow and accelerate the collection of receivables[15] - The board has reviewed cash flow forecasts and believes the group will have sufficient financial resources to meet its financial obligations over the next twelve months[16] - The financing costs slightly decreased by approximately HKD 978,000 to about HKD 4,902,000, primarily related to interest on outstanding lease liabilities[82] Revenue Streams - Revenue from the sale of bioregenerative, collagen, and anti-aging skincare products surged to HKD 21,990,000 in 2025, up from HKD 1,078,000 in 2024[33] - Revenue from accommodation operations and property facility management for the year was approximately HKD 26,730,000, a decrease of about 25.4% compared to the previous fiscal year, primarily due to a downturn in the Chinese hotel market and a reduction in occupancy rates[56] - The group recorded revenue of approximately HKD 29,315,000 in the accommodation business segment, a decrease of about 26.0% compared to the previous fiscal year’s revenue of approximately HKD 39,606,000[76] - The healthcare and beauty business contributed approximately HKD 21,990,000 in revenue for the year, a significant increase from HKD 1,078,000 in the previous year[76] Operational Strategies - The company is implementing a series of operational improvement plans, including enhancing accommodation project facilities and employee performance schemes, to improve service quality and customer satisfaction[56] - The company is actively adjusting its business strategies to develop personalized accommodation products and management services, aiming to enhance brand and product upgrades[55] - Management is focusing on enhancing the performance of the healthcare and beauty business segments to improve the group's financial condition[14] - The company is focusing on research and development in areas such as collagen-based products and targeted anti-aging therapies to gain a competitive edge[69] Corporate Governance and Compliance - The company has established a high standard of corporate governance to protect shareholder interests and maintain business integrity[99] - The audit committee reviewed the financial reporting procedures and internal controls, with no disagreements on the accounting policies adopted[101] - The company confirmed compliance with all relevant regulations and standards in Hong Kong and other applicable jurisdictions during the year[97] Future Plans and Developments - The company plans to change its English name to "Biosysen Limited" to better align with its future business development direction[51] - The company is pursuing the acquisition of a 37.5% stake in Beisheng Biotechnology, which has established a comprehensive synthetic biology infrastructure[72] - The company anticipates a net amount of approximately HKD 39,100,000 raised from a rights issue to support the development of its healthcare and beauty business[68] - The company announced a proposed acquisition of 100% equity in Ono Hong Kong Limited for a total consideration of HKD 22,000,000, with a deposit of HKD 15,000,000 paid as of December 31, 2025[50]
朸浚国际(01355) - 2025 - 年度业绩